Ask AI

Targeting BCMA in Early Relapsed/Refractory Myeloma: What Oncology Pharmacists Need to Know Now and in the Near Future

Improve your understanding of the efficacy and safety of BCMA-targeted therapies for patients with early relapsed/refractory multiple myeloma to better manage toxicities and improve patient outcomes through certified text modules, an expert-authored commentary, a podcast, and certified downloadable slides.

Share

Program Content

Events

Activities

Targeting BCMA in Early RR MM
Targeting BCMA in Early Relapsed/Refractory Myeloma: What Oncology Pharmacists Need to Know Now and in the Near Future
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 29, 2026

Provided by

ProCE Banner

Provided by ProCE, LLC.

Supporters

Supported by an educational grant from GSK.

GSK